news
30.06.10
Green Biologics are nominated in "Top 30 Most Transformative Technologies of 2010" poll
In Florida, Biofuels Digest announced the winners of its "30 Most Transformative Technologies of 2010" poll. The publication's readers submitted more than 48,000 votes from 3,500 ballots during the three-week voting process. The readers chose between transformative bioenergy technologies at more than 250 companies, universities and national laboratories, including 100 organizations that received write-in votes. Green Biologics was the only non-US biobutanol company to be named in the top 30. The following link provides more details:
http://www.chem.info/Products/2010/06/Alternative-Energy-30-Most-Transformative-Technologies-of-2010
02.06.10
GBL raises £4.9 million to deliver bio-butanol for biochemicals and biofuels
GBL is pleased to announce the completion of an investment round of £4.9 million to roll out its technology and commercialisation plans.
The round was led by Capricorn Venture Partners, a new investor in GBL through its Capricorn Cleantech Fund, and included participation by all GBL's existing institutional investors - Morningside Ventures, Carbon Trust Investment Limited and Oxford Capital Partners - as well as by management and founder investors.
Claude Stoufs, Senior Investment Manager at Capricorn Venture Partners, and David Brister, Operating Partner at Oxford Capital Partners, join the Board of GBL as part of this transaction.
Sean Sutcliffe, GBL Chief Executive welcomed the investment round:
"This investment underlines the leading position that GBL has taken in commercialisation of bio-butanol for the fast growing renewable chemicals and biofuels markets. Funds raised will allow us to accelerate our commercialisation programme in our key markets of China, India, Brazil and the US, by providing customers with retrofit packages to convert ethanol plants to bio-butanol and with fermentation and process technology solutions for existing and new build bio-butanol plants. It will also allow us to continue to invest in our technology development programme to reduce the production cost of bio-butanol from agricultural by-product and waste feedstocks for the advanced biofuel market.
We welcome the additional skills and experience brought to the Board by Claude Stoufs, who has a degree in Chemistry and over 30 years of technology development expertise, and by David Brister, who has a degree in Genetics and Zoology and over 20 years of involvement in the successful start up and development of commercial businesses."
Claude Stoufs, Senior Investment Manager for Capricorn Venture Partners, said:
"As a leading European cleantech investor, we are delighted to have successfully closed this significant round of financing in GBL. The areas of biochemicals and biofuels represent an important part of our cleantech investment strategy. We anticipate that GBL will be the first company in the world having its advanced proprietary industrial fermentation technology being used at full industrial scale to produce bio-butanol at competitive prices compared to butanol obtained by the petroleum-based oxo process. We are comfortable that the current round of financing will greatly contribute to reaching this ambitious objective."
26.10.09
Green Biologics make it into the Cleantech Connect 2009 Top 30 List
Green Biologics Ltd (GBL) has been listed in the prestigious Cleantech Connect 2009 Awards Top 30 List. The Cleantech Connect 2009 Award recognizes Sean Sutcliffe CEO said "We are delighted by the recognition given by inclusion of Green Biologics in the Cleantech Connect Top 30. GBL has continued to develop an international presence by providing innovative bio-process solutions for butanol. The technology produces environmentally friendly and sustainable biofuels with significant potential for GHG reduction. GBL continues to invest in technology development to drive the cost of production down further, enabling butanol as a leading next generation biofuel."
01.06.09
Professor Zhihao Sun joins GBL as a Scientific Advisor
Zhihao Sun is a Professor at the School of Biotechnology and Principal Investigator at the Biocatalysis Laboratory,
Prior to joining
Sean Sutcliffe, CEO comments: "We are honoured that Professor Sun is joining the Green Biologic's team. He is leading authority on the Chinese ABE process and brings a wealth of practical "hands on" process experience that will help us commercialise our advanced fermentation technology".
01.03.09
Dr Gerald Chan joins Board as Non Executive Director
Green Biologics (GBL) is delighted to announce that Dr Gerald Chan has joined the Board of GBL. This appointment comes alongside the completion of an investment round to continue the development of GBL's commercialization programme, in which Morningside participated alongside existing investors including Oxford Capital Partners and Carbon Trust Investments.
Dr Andrew Rickman, Chairman, commented, "We are delighted to welcome Dr Gerald Chan and Morningside to GBL. We particularly welcome the depth of experience that Gerald and Morningside bring to our successful commercialization programme in China, which is a key focus for the company, as well as their experience of nurturing successful global technology companies."
Gerald Chan co-founded Morningside in 1986. As a privately-held investment group, Morningside is active in both private equity and venture capital investments in North America, Europe and
Dr. Chan is currently a board member of Hang Lung Group and servesontheboards ofseveralprivatebiotechnology companies including Serica, Inc., Critical Biologics Corporation, CellCentric, Ltd., Inimex Pharmaceuticals, Inc.,Stealth Peptides Inc., and Vaccine Technologies Inc. Dr. Chan sits on the Science Advisory Council of UCLA, the Global Advisory Committee of the International Society for Stem Cell Research, the advisory board of
23.02.09
Professor David Jones joins GBL as a Scientific Advisor
Green Biologics Ltd (GBL) has appointed Professor David Jones as Scientific Advisor. David is a world leading expert on solventogenic Clostridia and their industrial application for the production of acetone, butanol and ethanol (ABE).
David has retired after a distinguished academic career with the Department of Microbiology,
Dr